Our community narratives are driven by numbers and valuation.
Telehealth is the future of healthcare in america and around the world. Most people don’t want to wait hours in the hospital or even weeks for an appointment.Read more
Pantoro Ltd is a mid-tier producer in Australia. They are producing around 100,000 oz (Norseman).Read more
As of April 12, 2025, Apple Inc. (AAPL) is navigating a complex landscape marked by significant challenges and resilient strengths.Read more

Overview VGRO is a diversified, low-cost ETF designed for long-term growth. It holds a mix of Canadian, U.S., and international equities , along with some fixed-income assets to provide stability.Read more
No modelo DCF a avaliação atual varia entre $2,06 com WACC 9,31% com taxa terminal de 2% (conservadora) O modelo de avaliação por comparação com os pares aponta para $2,29 O modelo Simply Wall Street com as mesmas premissas que utilizado no moderno DCF: WACC= 9,31% avalia a ação em $3,80 O PEG fwd aponta para PE =69X para 2025 e taxa crescimento EPS a médio prazo de 40% está um pouco sobrevalorida PEG=1,74. Para PEG=1 a ação estaria a cotar no 2,80 o que coincide com a cotação atual.Read more

Panasian Power Plc INTRODUCTION Panasian power plc is a pioneering supplier of clean and renewable energy which commenced operations in 2002 and has since become a leader in the renewable energy industry. PAP produces clean renewable energy from hydro, solar and other renewables sources in Asia and Africa.Read more
CSL Limited: Fair Value Assessment Amidst Evolving US Tariff Scenarios Executive Summary This report provides an assessment of the fair value of CSL Limited (CSL) under various potential United States (US) tariff scenarios. CSL, a global biotechnology leader with significant operations in plasma therapies (CSL Behring), influenza vaccines (CSL Seqirus), and iron/nephrology treatments (CSL Vifor), faces potential impacts from evolving US trade policies.Read more
Alibaba’s Outlook Brightens Amid Attractive Valuation Metrics Alibaba Group’s future is increasingly promising, supported by strong fundamentals and a compelling valuation relative to risk-free benchmarks. Using a forward earnings-based approach, the company’s fair value is estimated at $318 per share.Read more

1. £ 14 m mcap, £ 65 m revenue 2.Read more